This study represents the first systematic review and network meta-analysis to comprehensively evaluate the comparative efficacy and safety of three TPO-RAs—romiplostim, rhTPO, and eltrombopag—in pediatric ITP. The gene discussed is TPO; the disease is autoimmune thrombocytopenic purpura.